Mergers & Acquisitions - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

1 to 25 of 1224 results

AbbVie files NDA for oral, interferon-free treatment of hepatitis C

22-04-2014

US drugmaker AbbVie has submitted its New Drug Application to the US Food and Drug Administration for…

AbbVieAnti-viralsEnanta PharmaceuticalsFinancialNorth AmericaPharmaceuticalRegulationUSA

Novartis swaps products with GlaxoSmithKline, sells unit to Lilly

22-04-2014

In what looks like a significant restructuring of company focuses, Swiss drug major Novartis and UK peer…

Eli LillyGlaxoSmithKlineMergers & AcquisitionsNovartisPharmaceuticalVaccines

Sanofi divests Cell Therapy and Regenerative Medicine business to Aastrom

22-04-2014

US cardiovascular drug developer Aastrom Biosciences has entered into a definitive agreement to acquire…

Aastrom BiosciencesBiotechnologyMergers & AcquisitionsSanofi

Mega-mergers could be back in pharma sector, but is Pfizer bid for AstraZeneca likely to succeed?

22-04-2014

This weekend’s revelation about a possible acquisition of Anglo-Swedish drug major AstraZeneca by the…

AstraZenecaMergers & AcquisitionsPfizer

Pfizer said to be eyeing a $100 billion bid for AstraZeneca

20-04-2014

USA-based Pfizer, the world’s largest pharma company by sales, looks to be on the acquisition trail,…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi

18-04-2014

NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

OPKO to buy Israel’s Inspiro, gaining rights to new drug delivery technology

18-04-2014

US biopharma company OPKO Health has entered into a definitive agreement to acquire Inspiro Medical an…

Inspiro MedicalMergers & AcquisitionsOPKO HealthPharmaceuticalRespiratory and Pulmonary

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

SI Group acquires ibuprofen and antioxidants from Albemarle Corp

17-04-2014

Family-owned US chemical developer and manufacturer SI Group has signed a deal to acquire the antioxidants,…

AlbemarleAnalgesiaibuprofenMergers & AcquisitionsPharmaceuticalUSA

Epirus to acquire Zalicus, creating a publicly-traded biosimilars enterprise

16-04-2014

Boston-based privately-held Epirus Biopharmaceuticals, focused on the global development and commercialization…

BiosimilarsBiotechnologyEPIRUS BiopharmaceuticalsMergers & AcquisitionsZalicus

Bio-Techne to acquire China’s PrimeGene

15-04-2014

Techne Corp (d/b/a Bio-Techne) says that its R&D Systems China subsidiary has entered into an agreement…

Bio-TechneBiotechnologyMergers & AcquisitionsPrimeGene Bio-Tech

FTC imposes conditions on Akorn’s proposed buy of Hi-Tech Pharmacal

15-04-2014

In order to consummate the proposed $640 million acquisition of Hi-Tech Pharmacal by fellow USA-based…

ActavisAkornGenericsHi-Tech PharmacalMergers & AcquisitionsNorth AmericaUSA

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

AbbVie achieves response rate of 96% in Phase III trials of hepatitis C treatment

14-04-2014

US drugmaker AbbVie has revealed promising new results from its hepatitis C development program at the…

AbbVieAnti-viralsPharmaceuticalResearchUSA

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

Bristol-Myers’ all-oral daclatasvir and asunaprevir combo shines in Ph III

10-04-2014

US pharma major Bristol-Myers Squibb has presented new Phase III trial data of its combination therapy…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirPharmaceuticalResearch

Promising results for Merck & Co’s hepatitis C drug combo

Promising results for Merck & Co’s hepatitis C drug combo

10-04-2014

US pharma giant Merck & Co has announced additional data from the ongoing C-WORTHy study, a multi-arm…

Anti-viralsMerck & CoMK-5172PharmaceuticalResearch

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

10-04-2014

US antivirals major Gilead Sciences today announced positive findings from an open-label clinical trial…

Anti-viralsBiotechnologyGilead SciencesResearchSovaldi

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

Express Scripts forecasts unsustainable increases in specialty drug spend in USA

09-04-2014

Expensive treatments for broad patient populations are driving unprecedented growth in US spending on…

Anti-Arthritics/RheumaticsAnti-viralsMarkets & MarketingNorth AmericaOncologyPharmaceuticalPricingUSA

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

1 to 25 of 1224 results

Back to top